(Medical Xpress)—The CDC has issued a report detailing its findings in attempting to trace the increasing difficulty in treating gonorrhea, a sexually transmitted disease (STD) that can cause severe discomfort, serious ...
(HealthDay)—When an unnamed British man recently contracted a form of "super gonorrhea" resistant to the antibiotics commonly used to treat it, the news spiked concern in doctors and microbiologists worldwide.
Apr 27, 2018
0
56
(Medical Xpress)—The chief medical officer for Britain's Department of Health has issued a warning that resistance to bacteria is a more urgent threat to humanity than global warming, with bacteria becoming resistant to ...
The first new antibiotic for gonorrhea—the second most common sexually transmitted disease—has shown promise in a clinical trial.
Nov 3, 2023
0
38
Researchers at Public Health England have announced, as reported by the BBC, that a U.K. man has contracted a case of gonorrhea that is resistant to the two types of antibiotics that are normally used to treat such infections. ...
Sexually transmitted infections like chlamydia, gonorrhea and syphilis soared to new record highs in the United States last year, public health officials said Tuesday.
Aug 28, 2018
1
104
(HealthDay)—All sexually active women should be screened for two of the most common sexually transmitted infections: chlamydia and gonorrhea, according to new recommendations from the U.S. Preventive Services Task Force.
Sep 23, 2014
1
0
A test designed by UCLA researchers can pinpoint which people with gonorrhea will respond successfully to the inexpensive oral antibiotic ciprofloxacin, which had previously been sidelined over concerns the bacterium that ...
Aug 7, 2020
0
57
Researchers from UCLA have developed a laboratory test that helps physicians determine which people with gonorrhea may be more treatable with an antibiotic that has not been recommended since 2007 because of concerns that ...
May 23, 2017
0
0
Heard of gonorrhea? Most likely. What about gonococcal arthritis? Maybe not.
Apr 25, 2023
0
2
